Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer technology behind Novartis’ Pluvicto.
More Stories
Five Reasons why Telegram gaming could be 2025’s breakout success
Telegram’s mobile-first approach boosts tap-to-earn game popularity in emerging markets. Ease of access through channels and built-in wallets attracts new...
New government legislation could open up sports betting in Alberta, Canada by end of this year
Alberta’s Bill 16 will allow third-party operators in online gambling by 2025 The province aims to capture grey market bets...
August home sales drop more than expected, as prices set a new record
The median price of an existing home sold in August was $416,700, up 3.1% from August 2023.
UAW warns of potential strikes at Ford, Stellantis a year after unprecedented work stoppages
The UAW has announced a strike deadline at a Ford tool and die plant that supports F-150 production as well...
JetBlue to open airport lounges in New York and Boston in battle for big spenders
JetBlue joins Delta, American and United in opening airport lounges to cater to high-spending travelers.
Darden Restaurants earnings disappoint as Olive Garden, fine dining sales struggle
Olive Garden parent Darden Restaurants reported weaker-than-expected earnings and revenue for its fiscal first quarter.